Indeed, whereas NSCLC patients with exon 19 insertions or deletions are responsive to EGFR inhibitors, in-frame insertions in exon 20 confer drug resistance both in vitro and in vivo [48,49]. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.